Concerns in the Pharmaceutical Sector Amid Tariff Threats
This week, a significant concern arose for drugmakers as President Trump proposed implementing tariffs of up to 250% on imported medications. This news has unsettled the healthcare industry, leading to a 2.74% decline over the past five days, contributing to an overall drop of 5.13% this year.
Some major pharmaceutical companies felt the effects more than others. For instance, Novo Nordisk NYSE: NVO reported lower-than-expected revenue on August 6. Over the following days, it saw a decline of 5.79% but managed a slight recovery following disappointing results from Eli Lilly NYSE: LLY. Eli Lilly’s experimental weight loss medication did not meet market expectations, leading to an almost 11% drop in its stock value.
For investors looking at healthcare stocks, though, both NVO and LLY appear positioned to benefit from favorable long-term trends introduced by the current administration.
Trump’s Medicare and Medicaid Initiative
While the tariff threat is certainly a pressing concern, long-term investors might want to consider the broader picture. The recent initiative from the Trump administration could substantially alter prospects for both companies.
On August 1, it was reported that plans were being tested under Medicare and Medicaid to include coverage for expensive weight loss drugs such as Mounjaro and Ozempic. This proposal is part of a program managed by the Centers for Medicare and Medicaid Innovation (CMMI), set for release in January 2027.
If this plan is implemented, accessibility to anti-obesity medications would expand significantly, helping those unable to afford current prices for drugs like Wegovy and Zepbound, which can cost around $1,000 without insurance.
At the moment, insurance coverage for GLP-1 treatments is primarily focused on diabetes, with weight loss treatment options being excluded. Additionally, Medicaid coverage varies by state. However, if the administration’s plans come to fruition, there’s a chance that Medicare Part D and state Medicaid programs could voluntarily include these medications for weight management.
NVO and LLY as Leaders in Anti-Obesity Treatment
Despite some setbacks, Eli Lilly has demonstrated its strong position alongside Novo Nordisk in the GLP-1 weight loss treatment arena. Following its second-quarter earnings report on August 7, it was evident that the company had solidified its status among the best in this market. It beat revenue expectations and raised guidance for 2025, showing continued strong demand for its anti-obesity products.
Similarly, Novo Nordisk’s performance was robust, with analysts predicting $11.97 billion in revenue, which was slightly below expectations but still showed a sales uptick for its diabetes and weight loss medications by 16% compared to previous periods.
These two companies have effectively established themselves as the key players in the anti-obesity and diabetes medication sectors. And thanks to the current administration’s proposed integration of GLP-1 drugs into Medicare and Medicaid, sales growth for their flagship medications could see a significant boost.
A Bright Future for Weight Loss Drugs
Looking ahead, the anti-obesity drug market is already on a strong upward trajectory. According to market research from Grandview Research, it’s predicted to grow at a compound annual growth rate of 31.66% from 2024 to 2030.
Presently, North America dominates this market, accounting for 37.67% of revenues. In the U.S., the anti-obesity drug market is valued at $6.62 billion and is projected to reach $7.13 billion by 2030.
While Eli Lilly and Novo Nordisk may have seen drops of 14.49% and 44.22%, respectively, this year, 2023 could turn out to be pivotal if the Medicare and Medicaid pilot programs take flight. Value investors keen on the healthcare sector might find both stocks worth monitoring closely.
